Christopher Leidli’s Post

🎙️ In the inaugural episode of Baringa’s Pharmaceutical and Life Sciences Podcast, Baringa's expert Joshua Elliott sits down with Eric Walk MD, FCAP, Chief Medical Officer at PathAI, to explore the essential role of #strategicpartnerships between digital/AI and #biopharma organizations in shaping the future of #precisionmedicine. 🔍 Discover how to anticipate and prevent common challenges in your strategic #partnerships. 🎧 Listen here: https://lnkd.in/eF3KMQPd #biotech #pathology #digitalpathology #partnership #podcast

Made my BioSpace podcast debut today! Check out the latest episode of The Weekly now to hear me talk about BioMarin's restructuring and Terns pharma's weight loss pill data

On-demand Webinar: Avoid the costly pitfalls of antibody development. The early stages of antibody engineering often focus on binding, specificity, cross-reactivity, and so on at the expense of developability and manufacturability. This on-demand webinar explores the importance of incorporating developability assessments early in the drug discovery process to streamline optimization and ensure successful therapeutic development. Watch the webinar on demand: https://lnkd.in/eYEfGNeA #developabilityassesment #antibodydiscovery #antibodydevelopment #drugdiscovery #therapeuticsdiscovery #cmcdevelopment #podcast

BioWorld Insider Podcast: https://lnkd.in/e-nwr9rB Mark McKenna storms back with Mirador and eyes the development landscape BioWorld News In one of the biggest financings of the year so far, former Prometheus Biosciences Inc. CEO Mark McKenna helped raise $400 million to launch a new company, Mirador Therapeutics Inc. He didn’t sit on the sidelines for long after Merck & Co. Inc. bought Prometheus for $10.8 billion in 2023. He recruited key Prometheus executives to focus on Mirador’s genetic approach to drug discovery and precision medicine. McKenna said there was too much left undone to just hang back. In this BioWorld Insider episode, he talks about the new company and the multi-billion-dollar drugs that he believes provide sub-optimal efficacy compared to the tailor-made therapies he wants to develop. He also has deep insights into drug pricing and why the investment market is so tough on companies that don’t have A-plus science and teams.

In the In Conversation With series, a part of the free Drug Discovery World podcast, I speak with members of the drug discovery industry about their work and how it helps turn science into business.   In this episode, I'm in conversation with Dr Friso Postma, Vice President of AI Drug Discovery at BioXcel Therapeutics, Inc. Thanks to BioXcel’s AI platform, the company was able to repurpose previous drugs to obtain FDA approval for its acute treatment for agitation associated with schizophrenia and bipolar disorder, IGALMI, in April 2022, which was the first drug development success that involved the actual use of AI. Listen now.

The latest episode of CTI’s Moving Medicine Forward podcast is now live! We invite you to check out our new episode focused on #Transplantation. Join industry leaders as they delve into key developments. Highlights include: 1. Tim Schroeder sharing CTI’s transplant research journey 2. Bill Fitzsimmons discussing CTI’s key transplant involvement and how to enhance organ availability and reduce transplant failures 3. Dr. Robert Gatson’s impactful career and impact on transplantation Listen at https://bit.ly/4c0HO1F and don’t forget to subscribe. #MovingMedicineForward #CTIPodcast #Transplantation #CRO #ClinicalResearch #AdvancingHealthcareSolutions #ThinkGlobalActLocal

Listen to the new episode of Antibody News and keep up to date on global antibody therapeutic development!

On this week's episode of The Top Line podcast where all things biopharma and medtech are explained! The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This decision follows an investigation into the new safety signal from postmarketing adverse event reports and clinical trials. In today’s episode, Fierce Pharma's Angus Liu talks with regulatory experts Mwango Kashoki, M.D., and Steve Winitsky, M.D., to understand the rationale behind the FDA’s decision and to discuss its implications for CAR-T candidates and their developers down the line. Dive into the full episode by visiting: https://ow.ly/al4B50QJX4j Follow The Topline Podcast on Apple Podcasts, Spotify, Amazon or wherever you get your podcasts. #pharma #WeAreFierce #pharmaceuticals #biotech #FierceLifeSciences #biotechnews #FiercePharma #LifeSciences #podcasts #pharmanews

Drug delivery has advanced in recent decades, but targeted delivery to specific cell types remains a major challenge. In this podcast, Aptamer Group's own David Bunka, discusses some of the key differences between Optimer drug conjugates and antibody-drug conjugates (ADCs), such as their properties, how they are created, and potential immune responses. He also shares how Optimers can target malignant cells without prior knowledge of specific biomarkers, the scalability capabilities of Optimers due to their chemistry/being synthetically manufactured, and what long-term safety could look like. https://lnkd.in/emZQBkNU

How are companies like Vera Therapeutics, Inc. advancing autoimmune disease treatments? What does the current landscape of the biotech industry look like? Vera Therapeutics CEO and Founder Marshall Fordyce, M.D. joined host Rahul Chaturvedi on the Biotech2050 podcast to answer these questions. Dr. Fordyce also shares his entrepreneurial journey and delves into Vera Therapeutics' strategic pivot to focus on IG nephropathy and Vera’s development of atacicept, a promising B-cell modulator. Tune in: https://lnkd.in/eqHFpe4B #Biotech #AutoimmuneDisease